ANGO logo

ANGO
Angiodynamic Inc

1,067
Mkt Cap
$430.85M
Volume
512,364.00
52W High
$13.99
52W Low
$8.27
PE Ratio
-15.39
ANGO Fundamentals
Price
$10.36
Prev Close
$9.98
Open
$9.95
50D MA
$12.02
Beta
1.02
Avg. Volume
400,997.14
EPS (Annual)
-$0.8321
P/B
2.44
Rev/Employee
$433,330.37
Loading...
Loading...
News
all
press releases
Here's Why AngioDynamics (ANGO) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for AngioDynamics (ANGO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks·3d ago
News Placeholder
More News
News Placeholder
Reasons to Add AngioDynamics Stock to Your Portfolio for Now
ANGO stock is buoyed by strong fiscal Q2 results, surging NanoKnife adoption in prostate cancer, and broad Med Tech growth supporting margins.
Zacks·3d ago
News Placeholder
Zacks Research Cuts Earnings Estimates for AngioDynamics
AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) - Equities research analysts at Zacks Research decreased their Q3 2026 earnings per share estimates for shares of AngioDynamics in a note issued to...
MarketBeat·4d ago
News Placeholder
AngioDynamics J.P. Morgan Conference: MedTech Growth Push, Cash-Flow Path, CEO Retirement Plan
AngioDynamics (NASDAQ:ANGO) executives used a conference presentation hosted by J.P. Morgan to outline the company's multi-year portfolio transformation, highlight growth drivers across four key...
MarketBeat·18d ago
News Placeholder
The Zacks Analyst Blog Highlights AngioDynamics, Boston Scientific and Medtronic
AngioDynamics shows how product mix shifts toward higher-margin Med Tech platforms are quietly reshaping earnings power across medtech stocks.
Zacks·19d ago
News Placeholder
3 MedTech Stocks Benefiting From Favorable Product Mix Shifts
ANGO, BSX and MDT are showing earnings quality improve as higher-margin products take share, supporting margins and durable growth across MedTech.
Zacks·19d ago
News Placeholder
Down 25.0% in 4 Weeks, Here's Why You Should You Buy the Dip in AngioDynamics (ANGO)
AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks·21d ago
News Placeholder
ANGO Stock Dips Despite Q2 Earnings Beat, Gross Margin Improves
AngioDynamics reports flat Q2 earnings while revenue increase 8.8% and gross margin expands 170 bps on stronger Med Tech performance.
Zacks·25d ago
News Placeholder
AngioDynamics (ANGO) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·26d ago
News Placeholder
AngioDynamics (ANGO) Q3 2025 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·26d ago
<
1
2
...
>

Latest ANGO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.